Ascendis Pharma A/S business relationships

Companies named in Ascendis Pharma A/S’s 20-F filed 2026-02-11, and public companies whose annual reports name Ascendis Pharma A/S. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 5.5 / 10
AI naming: 86 / 100
Agent readiness: 35 / 100
AI adoption: 0 / 100

Layers: Peptides GLP-1 & obesity

Named in Ascendis Pharma A/S’s annual report 8

PFIZER INC (PFE)Partner7.7
“Pfizer (in collaboration with OPKO Health Inc.) has received regulatory approval of once-weekly somatrogon (brand name NGENLA) in more than 40 countries for pediatric GHD.” SEC filing
NOVO NORDISK A S (NVO)Licensor6.7
“This increase was primarily attributable to the continued growth of YORVIPATH global sales, partly offset by the recognition of a $100 million upfront payment in 2024 related to our exclusive license agreement with Novo Nordisk.” SEC filing
NOVO NORDISK A S (NVO)Partner6.7
“In January 2025, we announced that our multi-product collaboration with Novo Nordisk for TransCon technology-based therapies in obesity and metabolic diseases continues and that the lead program TransCon Semaglutide, remains on track to enter the clinic as anticipated.” SEC filing
OPKO HEALTH, INC. (OPK)Partner6.1
“Pfizer (in collaboration with OPKO Health Inc.) has received regulatory approval of once-weekly somatrogon (brand name NGENLA) in more than 40 countries for pediatric GHD.” SEC filing
Bachem (BCHMY)Supplier6.1
“We may purchase Bachem Product from other manufacturers and are not obligated to purchase Bachem Product from Bachem, other than certain quantities that have been forecasted by us in accordance with a mandatory rolling forecast that we must deliver to Bachem from time to time.” SEC filing
Lonza Sales AGSupplier5.2
“Our growth hormone parent drug as well as our TransCon hGH drug substance are supplied by both Fujifilm Diosynth Biotechnologies UK Limited ("Fujifilm"), and Lonza Ltd. Our PTH as well as our TransCon PTH drug substance is supplied by Bachem, Switzerland, pursuant to our agreement with Bachem.” SEC filing
CARBOGEN AMCIS AGCustomer4.7
“The intermediates of our proprietary TransCon linkers are made by CARBOGEN AMCIS AG under an agreement with CARBOGEN AMCIS AG and accompanying purchase orders.” SEC filing
CARBOGEN AMCIS AGSupplier4.7
“Manufacturing and Supply Agreement dated May 27, 2021, between Ascendis Pharma A/S and Carbogen Amcis AG.” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.